The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
Kelly, Kevin R. 1; Ecsedy, Jeffrey 2; Medina, Ernest 1; Mahalingam, Devalingam 1; Padmanabhan, Swaminathan 1; Nawrocki, Steffan T. 1; Giles, Francis J. 1; Carew, Jennifer S. 1,*
Journal of Cellular & Molecular Medicine.
15(10):2057-2070, October 2011.
(Format: HTML, PDF)